---
title: 'Guselkumab demonstrates long-term efficacy and maintenance of treatment response
  post-withdrawal in systemic-treatment na√Øve patients and non-responders to fumaric
  acid esters: Results from parts II and III of a randomised, active-comparator-controlled
  phase IIIb trial (POLARIS)'
date: '2023-12-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38133615/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231222170724&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In these exploratory analyses, guselkumab, as a first-line
  systemic treatment or second-line systemic treatment in FAE non-responders, was
  associated with long-term clinical efficacy up to Week 100, including a withdrawal
  ...'
disable_comments: true
---
CONCLUSIONS: In these exploratory analyses, guselkumab, as a first-line systemic treatment or second-line systemic treatment in FAE non-responders, was associated with long-term clinical efficacy up to Week 100, including a withdrawal ...